Vanguard Portfolio Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Vanguard Portfolio Management's AXSM Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Axsome Therapeutics (AXSM) stake by 0.55% in Q3 2026, selling an estimated $2.36M and leaving 1,972,645 shares worth $364M. The position accounts for 0.02% of the portfolio, ranked #824.
Vanguard Portfolio Management first reported a position in AXSM in Q1 2026 and has held it in 3 quarters since. The position peaked at $486M in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Vanguard Portfolio Management held 1,972,645 shares of Axsome Therapeutics worth $364M as of Q3 2026.
- Vanguard Portfolio Management sold 10,869 Axsome Therapeutics shares in Q3 2026, an estimated $2.36M.
- Axsome Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q3 2026, its #824 holding.
- Vanguard Portfolio Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Portfolio Management's Axsome Therapeutics position peaked at $486M in Q2 2026.
- 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.